MentionFox
Home › Stakes › Adaptimmune Therapeutics Plc
5%+ stakes · Schedule 13D and 13G

Adaptimmune Therapeutics Plc: 5%+ holders

Before you sign with, sell to or invest in Adaptimmune Therapeutics Plc

MentionFox check on Adaptimmune Therapeutics Plc: no red flags found in 6 sources; 1 item to note (checked 14 November 2026). mentionfox.com/c/stakes/adaptimmune-therapeutics

  • Note: Layoff plan disclosed Nov 2024 (filing)

New since last check: Layoff plan disclosed Nov 2024 (filing, first seen 14 November 2026).

Check Adaptimmune Therapeutics Plc before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Adaptimmune Therapeutics Plc?

Who has reported owning 5% or more of Adaptimmune Therapeutics Plc, from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

As of November 14, 2026, Adaptimmune Therapeutics Plc has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 5 filings are on record since August 13, 2025 (Schedule 13G, February 17, 2026).

New Enterprise Associates 14, L.P. also filed stake reports on 1 other company ↓

Sell to companies like Adaptimmune Therapeutics Plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · Holder: Long Focus Capital Management, LLC · Percent: 0% · SCHEDULE 13G
  • · Holder: Two Seas Capital LP · Percent: 0% · SCHEDULE 13G/A
  • · Holder: EcoR1 Capital, LLC · Percent: 4.2% · SCHEDULE 13G/A
  • · Holder: New Enterprise Associates 14, L.P. · Percent: 0% · SCHEDULE 13D/A
  • · Holder: Two Seas Capital LP · Percent: 8.5% · SCHEDULE 13G/A
At 5% or more0
Filings5
Latest filing2026-02-17

Adaptimmune Therapeutics Plc has 5 Schedule 13D or 13G filings on record since 2025-08-13. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2024-11-13 (layoff filings and notices).

Holders

HolderPercentSharesLatestEvent date
EcoR1 Capital, LLC4.2%66,000,000SCHEDULE 13G/A, 2025-08-192025-08-15
Two Seas Capital LP0%0SCHEDULE 13G/A, 2025-11-142025-09-30
New Enterprise Associates 14, L.P.0%4SCHEDULE 13D/A, 2025-08-192025-08-15
Long Focus Capital Management, LLC0%0SCHEDULE 13G, 2026-02-172025-12-31

Holding shares or following this stake? See who's behind Adaptimmune Therapeutics Plc and the warning signs.

Free to see. No signup.

Keep reading

More on Adaptimmune Therapeutics Plc and the records around it.

Companies that share a holder

Want the whole picture on Adaptimmune Therapeutics Plc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Adaptimmune Therapeutics Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Adaptimmune Therapeutics Plc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    6 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

New Enterprise Associates 14, L.P.

Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Ordinary Shares that were effected by the Reporting Persons during the past 60 days. Depending on market conditions and other factors, the Funds and other Reporting Persons may dispose of additional shares of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-08-19

Timeline

FiledHolderPercentFiling
2025-08-13Two Seas Capital LP8.5%SCHEDULE 13G/A
2025-08-19EcoR1 Capital, LLC4.2%SCHEDULE 13G/A
2025-08-19New Enterprise Associates 14, L.P.0%SCHEDULE 13D/A
2025-11-14Two Seas Capital LP0%SCHEDULE 13G/A
2026-02-17Long Focus Capital Management, LLC0%SCHEDULE 13G

Tools for this story

Each opens in a new tab, filled in for Adaptimmune Therapeutics Plc. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/adaptimmune-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who owns 5% or more of Adaptimmune Therapeutics Plc? Stakes filed. MentionFox, 2026-11-14. https://mentionfox.com/stakes/adaptimmune-therapeutics